Simvastatin Myopathy Rate Spells Trouble For High Doses In “A to Z” Trial
This article was originally published in The Tan Sheet
An increased rate of myopathy in study participants taking an 80 mg dose of Merck's Zocor (simvastatin) suggests that high doses of the drug "should be used with caution," according to an editorial slated for publication in the Sept. 15 Journal of the American Medical Association
You may also be interested in...
J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD
Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC